BriaCell Therapeutics Corp. (BCTX)
NASDAQ: BCTX · IEX Real-Time Price · USD
2.030
-0.110 (-5.14%)
At close: Apr 19, 2024, 3:55 PM
2.160
+0.130 (6.40%)
After-hours: Apr 19, 2024, 5:06 PM EDT
Company Description
BriaCell Therapeutics Corp. operates as a Phase 3 biotechnology company transforming cancer care with its novel cellular immunotherapies.
It is conducting a pivotal Phase 3 clinical trial in advanced breast cancer with its Bria-IMT in combination with an immune check point inhibitor.
It is also developing personalized off-the-shelf treatments for breast cancer, prostate cancer, and other cancers.
The company has a collaboration with Incyte Corporation to evaluate combination of the Bria-IMT. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.
BriaCell Therapeutics Corp.
| Country | Canada |
| Founded | 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 16 |
| CEO | Dr. William V. Williams M.D. |
Contact Details
Address: 3rd Floor, Bellevue Centre, 235-15th Str West Vancouver, A1 V7T 2X1 British Columbia, Canada | |
| Phone | (604) 921-1810 |
| Website | briacell.com |
Stock Details
| Ticker Symbol | BCTX |
| Exchange | NASDAQ |
| Fiscal Year | August - July |
| Reporting Currency | USD |
| CIK Code | 0001610820 |
| CUSIP Number | 10778Y302 |
| ISIN Number | CA1079301091 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. William V. Williams M.D. | Chief Executive Officer, President and Director |
| Gadi Levin B.Com., C.A., CPA, M.B.A. | Chief Financial Officer and Corporate Secretary |
| Dr. Miguel A. Lopez-Lago Ph.D. | Chief Scientific Officer |
| Dr. Giuseppe Del Priore M.D., M.P.H., MPH | Chief Medical Officer |
| Dr. Charles Louis Wiseman FACP, M.D. | Founder, Principal Research Advisor and Member of Scientific Advisory Board |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 2, 2024 | 8-K | Current Report |
| Mar 18, 2024 | 10-Q | Quarterly Report |
| Jan 31, 2024 | EFFECT | Notice of Effectiveness |
| Jan 31, 2024 | 8-K | Current Report |
| Jan 29, 2024 | UPLOAD | Filing |
| Jan 22, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| Jan 9, 2024 | DEF 14A | Other definitive proxy statements |
| Jan 8, 2024 | SCHEDULE 13G | Filing |
| Dec 20, 2023 | 8-K | Current Report |
| Dec 14, 2023 | 10-Q | Quarterly Report |